Guo Yan

Woo Kwang Min, Guo Yan, Mehrabian Zara, Miller Neil R, Bernstein Steven L

This study developed a new bilateral epidural electrode method for flash VEPs in rats. It significantly improves signal-to-noise and accuracy for comparing visual function between eyes, enhancing preclinical glaucoma research and reducing animal use.

Zhang Yangzhou, Yang Huiling, Pu Jipu, Guo Yan

This meta-analysis found laser trabeculoplasty and drug therapy similarly effective for OAG IOP control. LT reduces medication need and is a safe, viable first-line option, especially selective LT.

Johnson Mary A, Mehrabian Zara, Guo Yan, Ghosh Joy, Brigell Mitchell G, Bernstein Steven L

An anti-NOGO antibody in rats with NAION preserved optic nerve function and reduced inflammation. This suggests a potential neuroprotective treatment for this currently untreatable condition.

Huo Yanjiao, Thomas Ravi, Guo Yan, Zhang Wei, Li Lei, Cao Kai et al.

This study found macular microcirculation significantly declined in mild and severe glaucoma, but not between mild and moderate stages, linking it to age, visual field loss, and nerve thinning.

Huo Yan J, Guo Yan, Li Lei, Wang Huai Z, Wang Ya X, Thomas Ravi et al.

This study found mGCIPL thickness linearly decreases with age, with steep drops in the fifth and seventh decades, and is associated with pRNFL and IOP. This helps interpret OCT scans for glaucoma progression.

Miller Neil R, Johnson Mary A, Nolan Theresa, Guo Yan, Bernstein Steven L

This primate study found a single ranibizumab injection immediately after NAION onset offered no neuroprotection, suggesting it's ineffective for preserving vision in this condition.

Mathews Michaela K, Guo Yan, Langenberg Patricia, Bernstein Steven L

CNTF preserved retinal ganglion cells in a rodent NAION model, significantly reducing cell loss. This suggests CNTF could be a promising treatment for human NAION.

Slater Bernard J, Vilson Fernandino L, Guo Yan, Weinreich Daniel, Hwang Shelly, Bernstein Steven L

Rodent NAION causes optic nerve demyelination. GM-CSF increased inflammation and reduced RhoA activity, but didn't protect RGCs or improve regeneration, highlighting demyelination's role in NAION's functional defects.

Touitou Valerie, Johnson Mary A, Guo Yan, Miller Neil R, Bernstein Steven L

A single intravitreal PGJ2 injection was safe and neuroprotective in a rodent AION model, preserving RGCs and vision. This offers a potential treatment for NAION.

Bernstein Steven L, Guo Yan

Rodent AION impacts amacrine cells; moderate injury alters their signaling without loss, while severe injury causes amacrine cell loss, suggesting RGC-amacrine communication disruption and direct ischemic damage.

Slater Bernard J, Mehrabian Zara, Guo Yan, Hunter Allan, Bernstein Steven L

rAION causes regional RGC apoptosis over several weeks, peaking at 2-3 weeks. This prolonged death window suggests a longer therapeutic opportunity for NAION treatment than previously thought.

Bernstein Steven L, Guo Yan, Slater Bernard J, Puche Adam, Kelman Shalom E

Rodent NAION models showed optic nerve infarcts cause transient RGC stress followed by significant RGC loss correlating with axonal damage, informing glaucoma research.

Goldenberg-Cohen Nitza, Guo Yan, Margolis Frank, Cohen Yoram, Miller Neil R, Bernstein Steven L

This study found that in experimental AION, oligodendrocytes experience progressive stress, dysfunction, and death, leading to demyelination distant from the lesion. This highlights oligodendrocytes as a neuroprotection target.

Bernstein Steven L, Guo Yan, Kelman Shalom E, Flower Robert W, Johnson Mary A

This study developed a rodent AION model, finding rapid functional and cellular changes mimicking human AION. This model offers a platform for detailed disease analysis and therapeutic development.